The study underwent major protocol amendments throughout its development program due in part to sponsor changes-the population was enriched to high risk then changed back to all- comers, follow-up was truncated at 2-years changing the primary analysis from event-driven to time-driven, and patients were reconsented for extended follow-up for 5-years post- randomization. However, these changes appear to be due to outside factors (i.e. external information and organizational changes) rather than premature trial unblinding.